Patents Examined by Melissa S Mercier
  • Patent number: 11229592
    Abstract: The present invention is in the field of hair treatment compositions; in particular relates to a method for hair volume reduction. Despite the prior art, there still exists the opportunity to increase the conditioning benefits delivered through hair treatment compositions. It is therefore an object of the present invention to provide a method that retains shape and reduces frizz even after exposure to humidity and washing the hair. It has been found that reduced hair frizz and hair shape retention even after exposure to moisture can be obtained by using N-formyl amino acids.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: January 25, 2022
    Assignee: Conopco, Inc.
    Inventors: Prem Kumar Cheyalazhagan Paul, Susan Pye, Charlotte Breony Tandy Rogers
  • Patent number: 11229549
    Abstract: A contact lens or conjunctival cover, including an internal absorbent medium; an external carrier medium; the external carrier medium having openings therein that allow fluid to pass between an exterior of the contact lens or conjunctival cover and the internal absorbent medium thereby to be absorbed and released by the internal absorbent medium. Also, a method of treating dry eye syndrome, including: gathering donor tears from eyes of an individual having healthy tears; storing the donor tears in an absorbent medium; placing the absorbent medium with the donor tears absorbed therein in contact with an eye or eyes affected by dry eye syndrome; and dispersing the donor tears over an ocular surface of the eyes affected by dry eye syndrome.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: January 25, 2022
    Inventor: Vance M. Thompson
  • Patent number: 11219601
    Abstract: The present invention provides an emulsified gel composition comprising a physiologically active substance, water, a gelling agent, an anti-peeling agent, and a surfactant having an HLB value of 18 to 20, in which the gelling agent is a nonionic water-soluble polymer, and the anti-peeling agent is one or more compounds selected from the group consisting of sucrose, sorbitol, polyethylene glycol, glycerin, a (meth)acrylic-based polymer compound, and a polyoxyethylene hydrogenated castor oil.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: January 11, 2022
    Assignee: HISAMITSU PHARMACEUTICAL CO., INC.
    Inventors: Shinya Matsumura, Toshihiro Nakanishi, Yasuhisa Kose
  • Patent number: 11219291
    Abstract: The invention relates to a false nail comprising at least: one front layer (12) forming the body of the false nail (1), and a rear layer (11) of an adhesive material for attaching the body of the false nail to a natural nail. The rear layer (11) is formed by a fast-drying polymer adhesive with desiccating capacity, and the front layer (12) is made of a composite material and comprises at least a first layer (12a) of micro-hybrid composite with low contraction capacity in contact with the polymer adhesive. The invention also relates to a method for shaping the false nail on a natural nail and the use of composite material to shape same.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: January 11, 2022
    Inventor: Manuel Enrique Toral Bardina
  • Patent number: 11219655
    Abstract: The invention relates to medicines, and more particularly to an abortion medication and an administration thereof, where the abortion medication contains 40-60 mg/mL of a kidney bean lectin. The invention also provides another abortion medication, which contains 40-60 mg/mL of a kidney bean lectin, 40-50 mg/mL of an oligosaccharide and 6-9 mg/mL of NaCl. The two abortion medications provided herein are both capable of effectively terminating the pregnancy and are safe without toxic side effects. Moreover, these drugs can be reused several times. These abortion medications are administered intrauterinely, which enables the kidney bean lectin therein to show the best abortive effect, and the local administration of these drugs in the uterine cavity has relatively simple operation.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: January 11, 2022
    Assignee: YUNNAN KANG-ZHOU BIOTECH CO., LTD.
    Inventors: Kangmin Wang, Hong Zhao, Guizhen Lu, Chun Wu, Lifen Zhang, Chenghuan Yang, Jingjing Wang
  • Patent number: 11219599
    Abstract: A method of making an oral soluble film, containing at least one active agent, includes providing a well of a predetermined size; depositing a film forming composition in the well; depositing an active agent composition in the well, the active agent composition being different than the film forming composition, the film forming composition and the active agent composition forming an admixture in the well; and drying the admixture in the well. Alternatively, the method includes providing a well of a predetermined size; depositing a film forming composition including at least one active agent in the well, the film forming composition having a viscosity below 2000 centipoise; and drying the film forming composition in the well.
    Type: Grant
    Filed: June 29, 2021
    Date of Patent: January 11, 2022
    Assignee: NOVA THIN FILM PHARMACEUTICALS LLC
    Inventors: Richard C. Fuisz, Joseph M. Fuisz
  • Patent number: 11213029
    Abstract: The present invention relates to a composition for controlling plant diseases containing a limonene derivative as an active ingredient. In the present invention, the limonene derivatives have an effect of inhibiting the growth of Xanthomonas oryzae pv. Oryzae (Xoo), which is a pathogen mediating bacterial leaf blight, and Magnaporthe oryzae, which is a pathogen mediating rice blast, and it was confirmed in an experiment with respect to inhibition using volatility (i.e., in a state not being in direct contact with Xoo or M. oryzae) that the limonene derivatives have a growth inhibitory effect. Accordingly, the limonene derivatives have an inhibitory effect against the growth of Xoo and thus they can be effectively used as a composition for controlling plant diseases.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: January 4, 2022
    Assignee: KOREA ATOMIC ENERGY RESEARCH INSTITUTE
    Inventors: Sungbeom Lee, Gun Woong Lee, Kwangwoo Jung, Byung Yeoup Chung, Seungsik Lee, Jin-Hong Kim, Hyoungwoo Bai, Yong-Dae Park
  • Patent number: 11207287
    Abstract: A combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin, and a medical product or pharmaceutical composition comprising such combination, useful for the treatment of a variety of diseases and conditions is described. The combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin is also useful for cosmetic treatment of skin and as an antibacterial agent.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: December 28, 2021
    Assignee: IASOMAI AB
    Inventors: Tiziana Parasassi, Graziella Costa, Ewa Krasnowska, Eugenia Pittaluga
  • Patent number: 11202763
    Abstract: To provide a phosphatidylcholine transdermal absorption preparation containing phosphatidylcholine in an adhesive layer. A phosphatidylcholine transdermal absorption preparation has a configuration in which an adhesive layer formed on at least one side of a support contains phosphatidylcholine, an adhesive component, and a lipophilic component, and thus the preparation becomes a patch-type transdermal absorption preparation which acts as a fat-decreasing agent which contains phosphatidylcholine and can exert an effect that local obesity such as subcutaneous fat is dissolved and fat is decreased by transdermal absorption of phosphatidylcholine as the preparation is pasted to the skin of a human body since phosphatidylcholine can be stably present in the adhesive layer and has an advantage due to the patch dosage form that the preparation can be fixed to the affected area and is more favorably handled as compared to liquid preparations and the like.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: December 21, 2021
    Assignee: UNISH INC.
    Inventor: Hirofumi Nakanishi
  • Patent number: 11202757
    Abstract: A pharmaceutical composition in a form of dry powder for intranasal administration includes solid particles of at least one opioid receptor antagonist as active ingredient and two types of solid particles. A naloxone pharmaceutical composition in the form of dry powder for intranasal administration, including as active agent naloxone or a pharmaceutically acceptable salt thereof. A kit for intranasal administration of naloxone. A method of treating opioid overdose/intoxication and/or a symptom thereof in a patient in need thereof by intranasally administering a therapeutically effective amount of a composition including solid particles of at least one opioid receptor antagonist as active ingredient and two types of solid particles.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: December 21, 2021
    Assignee: Formulex Pharma Innovations Ltd.
    Inventors: Galia Temtsin-Krayz, Dalia Megiddo, Tair Lapidot, Carolina Abrutzky
  • Patent number: 11185540
    Abstract: Pharmaceutical compositions of one or more opioid antagonists or phosphodiesterase 5 (PDE5) inhibitors are disclosed.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: November 30, 2021
    Assignee: PARDON MY SCOTCH LLC.
    Inventor: Michael Anthony Pavlovich
  • Patent number: 11185484
    Abstract: A solid anhydrous composition for caring for and/or making up keratin materials comprising: a) at least one triglyceride oil according to formula (I): CH2(OOCR1)CH(OOCR2)CH2(OOCR3) (I) wherein R1, R2 and R3 are independently chosen from C6-C30 alkyl and C6-C30alkenyl; b) at least one triglyceride oil according to formula (II): CH2(OOCR1)CH(OOCR2)CH2(OOCR3) (II) wherein R1, R2 and R3 are independently chosen from C6-C30 alkyl and C6-C30alkenyl, at least one of R1, R2 and R3 is substituted with a hydroxyl; c) at least one pasty compound chosen from an ester of dimer dilinoleic acid and polyol(s) or an ester thereof, and d) at least one wax, wherein the triglyceride oil according to formula (I) and the triglyceride oil according to formula (II) are present in the solid anhydrous composition in a weight ratio less than or equal to 1:1.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: November 30, 2021
    Assignee: L'OREAL
    Inventor: Chunlei Yao
  • Patent number: 11185614
    Abstract: The present invention relates to balloon catheters with or without crimped stent, whose surface is coated with at least one antirestenotic agent and at least one transport promoting molecular dispersant, as well as a method for the preparation of these medical devices.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: November 30, 2021
    Assignee: Hemoteq AG
    Inventors: Erika Hoffmann, Michael Hoffmann, Roland Horres
  • Patent number: 11179330
    Abstract: The present invention provides an oral transmucosal film or patch for delivering doxepin through the buccal mucosa or sublingual mucosa. The film or patch is a bilayer structure containing a mucoadhesive layer with amorphous doxepin and soluble backing layer without doxepin. The film or patch has satisfactory bioavailability and improved palatability. The mucoadhesive layer comprises 0.5-25% (w/w) of doxepin, 50-96% of one or more film-forming agents, 1-30% (w/w) of one or more adhesives, and 0.05-5% (w/v) of one or more stabilizers. The backing layer comprises 80-100% (w/w) of one or more film-forming agents. Preferred adhesives include povidone, carbomer, and polycarbophil. Preferred stabilizers include butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), citric acid, and ascorbic acid.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: November 23, 2021
    Assignee: Xiamen LP Pharmaceutical Co., Ltd.
    Inventors: Liyan Xie, Yuantao Song, Shengkai Cao, Zhoue Gao, Rongbin Ling
  • Patent number: 11173114
    Abstract: An oral soluble film contains at least one active agent. Alternatively, a multi-layered film includes a plurality of layers, at least one at least one of the plurality of layers being an oral soluble film layer containing at least one active agent. The oral soluble film may be made, e.g., by a method comprising providing a well of a predetermined size; depositing a film forming composition in the well; metering a predetermined amount of an active agent composition in the well separately from the film forming composition, the active agent composition being different than the film forming composition, the film forming composition and the active agent composition forming a single layer in the well; and drying the single layer in the well to form the oral soluble film containing the at least one active agent.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: November 16, 2021
    Assignee: NOVA Thin Film Pharmaceuticals LLC
    Inventors: Richard C. Fuisz, Joseph M. Fuisz, Madhu Hariharan
  • Patent number: 11160754
    Abstract: Disclosed herein are compositions and methods for treating lung disorders including lung tumors by pulmonary administration of compositions comprising taxane particles such as docetaxel or paclitaxel particles.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: November 2, 2021
    Assignee: CritiTech, Inc.
    Inventors: Michael Baltezor, Matthew McClorey, William Johnston, Gere S. diZerega, James Verco
  • Patent number: 11154566
    Abstract: The present invention is about composition for preventing hair loss or promoting hair growth comprising indirubin derivatives; and one or more selected from the group consisting of Euodia daniellii extract, Persicaria hydropiper extract, Hovenia dulcis extract, methyl vanillate, hesperidin and quercitrin; as an active ingredient. In addition, one or more selected from the group consisting of Euodia daniellii extract, Persicaria hydropiper extract, Hovenia dulcis extract, methyl vanillate, hesperidin and quercitrin of the present invention is a natural-derived composition with little toxicity to cells. Indirubin derivatives are stable compounds that have been found to have little toxicity to the human body, and therefore, when used in a mixture thereof, there are advantages in that they do not exhibit adverse effects on the human body, unlike conventional steroid drugs.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: October 26, 2021
    Assignee: CK BIOTECH
    Inventors: Kang-Yell Choi, Jiyong Shim, Yeong Chan Ryu, Jiyeon Park
  • Patent number: 11154640
    Abstract: A scaffold of hollow fibers comprising a mixture of polylactic acid (PLA) and polybutylene succinate (PBS) and cellulose nanofibers (CNF), medical products made of these scaffolds and methods of using the scaffolds in regenerative medicine. A method for producing the scaffolds is also disclosed.
    Type: Grant
    Filed: June 1, 2021
    Date of Patent: October 26, 2021
    Assignee: King Abdulaziz University
    Inventors: Tuerdimaimaiti Abudula, Usman Saeed, Hamad Al-Turaif, Ahmed Alshahrie
  • Patent number: 11147774
    Abstract: The present invention provides a liquid composition comprising a pharmaceutically active compound and an aqueous polymer dispersion, wherein said liquid composition forms a film upon drying under standard ambient temperature and pressure; a method for providing the same; and a container comprising said liquid composition.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: October 19, 2021
    Assignee: OYSTERSHELL NV
    Inventor: Bart Rossel
  • Patent number: 11147901
    Abstract: A scaffold of hollow fibers comprising a mixture of polylactic acid (PLA) and polybutylene succinate (PBS) and cellulose nanofibers (CNF), medical products made of these scaffolds and methods of using the scaffolds in regenerative medicine. A method for producing the scaffolds is also disclosed.
    Type: Grant
    Filed: June 1, 2021
    Date of Patent: October 19, 2021
    Assignee: King Abdulaziz University
    Inventors: Tuerdimaimaiti Abudula, Usman Saeed, Hamad Al-Turaif, Ahmed Alshahrie